Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

Issue of 13 Ordinary Shares

Purchase and Cancellation of Deferred Shares

Total Voting Rights

PDMR Dealing

22 January 2025 - Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that 13 ordinary shares of 0.1 pence each (the "Ordinary Shares", such Ordinary Shares being the "New Shares") were issued at an aggregate consideration of £1.001 for the purpose of financing the purchase of 9,848,333 deferred shares of 0.1 pence each (the "Deferred Shares") yesterday.  Each of Dr. Shaun Furlong, Chief Financial Officer of the Company, and Karley Cheesman, company secretary of the Company, has subscribed for 7 New Shares and 6 New Shares, respectively. Subsequent to the issue of the New Shares, Dr. Shaun Furlong will hold 1,507 Ordinary Shares.  In addition, the Deferred Shares have been purchased by the Company and subsequently cancelled yesterday.

The Company is pleased to confirm that, in accordance with the terms set out in its articles of association and pursuant to the terms of a repurchase contract approved by the shareholders at the Annual General Meeting held on 16 December 2024, all outstanding Deferred Shares have been purchased by the Company and subsequently cancelled. As such, there are no longer any Deferred Shares in issue. The purchase and cancellation of the Deferred Shares have no impact on the Ordinary Shares in issue.

Details of the purchase of the Deferred Shares can be found in the notice of the Annual General Meeting available on the Company's website: https://www.allergytherapeutics.com/investors/shareholder-services/agm-information.

Total Voting Rights

In accordance with DTR 5.6.1 of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTR"), as at the date of this announcement, the Company has 4,766,439,951 Ordinary Shares in issue. There are no shares held in treasury. The total number of voting rights in the Company is therefore 4,766,439,951.

The above figure of 4,766,439,951 may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under DTR.

- ENDS -

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

Notes for editors:

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Company sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

 Notification and public disclosure of transactions by Director/persons discharging managerial responsibilities ("PDMR") and persons closely associated with them ("PCA")